UNSPSC 51392211: Mivazerol or piroximone

This classification denotes an alpha-adrenergic agonist with the molecular formula C11H11N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5P1SSA8KD, chemically known as alpha-imidazol-4-yl-2,3-cresotamide but generally known as mivazerol, which bears US NIH Compound Identifier 60784. European Medicines Agency schedules Mivazerol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09015MIG.

The term MIVAZEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Mivazerol or piroximone bears US NLM identifiers UMLS ID C0071150 and NCI Concept Code C90921. SMILES: CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2.

UNSPSC 51392211 Mivazerol or piroximone is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though the recent solicitation record shows a mismatch between the code's nominal scope and actual buying activity. Seminole County, Florida posted an IFB for naloxone and safe drug deactivation systems — opioid-reversal medication and drug disposal equipment — rather than the specific pharmaceuticals the code nominally names. The issuing body represents county-level health procurement focused on community health initiatives and emergency response capabilities, with requirements for quarterly deliveries, drug-free workplace certification, E-Verify compliance, workers' compensation insurance, and a two-year initial term with optional one-year renewal.

The single recent opportunity identified comes from Florida, specifically Seminole County, which sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through IFB 60459723LAS with a response deadline of July 26, 2023. The mismatch between the code's name and the naloxone procurement suggests this Commodity code may see limited activity under its stated scope, or state procurement systems are applying it inconsistently to pharmaceutical-adjacent health products. Without additional recent opportunities in the record, the geographic and issuing-body patterns cannot be reliably characterized beyond this single county-level solicitation.